Previous studies have reported that decreased serine 208 phosphorylation of troponin T (TnTpSer208) is associated with ischaemic heart failure (HF), but the molecular mechanisms and functional consequences of these changes are unknown. The aim of this study was to characterize the balance between serine phosphorylation and O-Nacetylglucosaminylation (O-GlcNAcylation) of TnT in HF, its mechanisms, and the consequences of modulating these post-translational modifications.
Introduction
Heart failure (HF) following myocardial infarction (MI) is characterized by alterations of left ventricle (LV) structure and function, known as LV remodelling; 1 this pathophysiological process is a strong predictor of both HF and death. 2, 3 Evaluation of post-translational modifications (PTM) of cardiac proteins is a promising new approach to studying the mechanisms of HF. The phosphorylation status of sarcomeric proteins is altered in HF and may thus contribute to the decreased pump function. 4 Another rapid, dynamic, and reversible PTM is O-N-acetylglucosaminylation (O-GlcNAcylation). 5 Both phosphorylation and O-GlcNAcylation regulate numerous cellular functions by reversibly adding either phosphate 6 or O-N-acetylglucosamine (O-GlcNAc) 7 to proteins. The crosstalk between these two PTMs may occur by steric competition for occupancy at the either the same or a proximal amino acid site. 8 The † These authors contributed equally to this work.
description of specific sites of O-GlcNAcylation of some cardiac myofilament proteins raises the possibility that O-GlcNAc and O-phosphate modifications of these proteins interact dynamically. 9, 10 We recently showed that ischaemic HF is associated with decreased myocardial and plasma levels of phosphorylated serine 208-troponin T (TnTpSer208) in rats. 11, 12 According to in vitro studies, increased
TnT phosphorylation reduces muscle contraction, but in vivo studies report contradictory observations, as discussed in a recent review. 13 Whether TnTSer208 phosphorylation decreases in cardiac dysfunction
has not yet been explored. Phosphorylation that depends on protein kinase C (PKC) and protein kinase A (PKA) modulates troponin activity by direct modulation of myofilament contraction force. 14 Because the phosphorylation status of sarcomeric proteins is regulated by a wellcontrolled kinase-phosphatase balance in cardiac myocytes, 15 we postulated that the decrease of TnTpSer208 in HF involves a change in the balance between kinases and phosphatases and that these changes in TnT phosphorylation are paralleled by changes in O-GlcNAcylation. Our objectives were therefore (i) to characterize the signalling enzymes involved in the phosphorylation and O-GlcNAcylation of TnT; (ii) to study the impact on cardiac function of the enzymes involved in TnT PTM; and (iii) to determine whether crosstalk between phosphorylation and O-GlcNAcylation of TnT occurs in the heart.
Methods
More details of the methods are described in the Data Supplement.
Animal models
All animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication NO1-OD-4-2-139, revised in 2011). Animals were used and experimental protocols performed under the supervision of a person authorized to perform experiments on live animals (F. Pinet: 59-350126, exp. date: 22 June 2016). Approval was granted by the institutional ethics review board (CEEA Nord Pas-de-Calais N 242011, January 2012). Before surgery, animals were anaesthetized (sodium methohexital, 50 mg/kg IP), while analgesia was administered before (xylazine 5 mg/kg IP) and 1 h after surgery (xylazine 50 mg/kg subcutaneously) as described. 16 Anaesthesia and sedation were controlled by monitoring heart rate. MI was induced in 10-week-old male Wistar rats (n ¼ 19) (Janvier, Le Genest St isle, France) by ligation of the left anterior descending coronary artery. 16, 17 Haemodynamic and echocardiographic measurements (see Supplementary material online, Table S1 ) were taken 2 months after surgery, followed by heart excision, as previously described. 11, 18 Hearts from F2 hybrid PKC1+/+ (n ¼ 6) and PKC12/2 (n ¼ 6) C57BL/6J X129S4/SvJae F1 mice, 6-to 13-week-old mice littermates, were kindly provided by Robert Messing. 19 
Isolated heart perfusion
In vitro LV function was determined in randomly selected control male Wistar rats, some untreated, others treated 2 h before heart excision with either 100 mL 1V1-2, a PKC1 inhibitor (200 mmol/L, Anaspec, Seraing, Belgium), or 100 mL Thiamet G, 20 an OGA inhibitor (200 mmol/L, Sigma-Aldrich, Lyon, France).
Cell culture
Rat cardiac myoblasts (H9c2 cells) were obtained from the ATCC (CRL-14146). Primary cultures of rat neonatal contractile cardiac myocytes (NCM) were prepared from heart ventricles of 1-or 2-day-old rats killed by decapitation as previously described, with minor modifications. 21 We used the first two individual pre-designed specific siRNA specifically targeting rat PKC1 mRNA and rat OGT, as well as non-targeting control (ON-TARGETplus siRNA, Dharmacon, Thermo Scientific, France).
Biphotonic confocal microscopy was used for the imaging of 4% paraformaldehyde and 0.1% triton fixed/permeabilized H9c2 and NCM cells.
Atomic force microscopy
Experiments on NCMs used atomic force microscopy (AFM), performed with a JPK NanoWizard3 atomic force microscope, mounted on a Zeiss AxioObserver.Z1.
Tissue fractionation, enzyme activities, antibodies, and western blot
Western blot experiments were performed with LV proteins and H9c2 and NCM extracts, as previously described.
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Detailed protocols and a list of reagents are provided in the Data Supplement.
Mapping of the O-GlcNAc sites in troponin T
The O-GlcNAc antibody (200 mg RL2) was used for immunoprecipitation with slight modifications from a previous publication. 22 The nucleocytoplasmic isoform of human OGT (ncOGT) was expressed and purified as described. 23 Peptides (see Supplementary material online, Table S2 ) were solubilized for the O-GlcNAcylation reactions before analysis by mass spectrometry and NMR.
Statistical analysis
Data are expressed as means + SEM. Statistical analysis of the functional cardiac indicators used the Wilcoxon test. For the other analyses, an unpaired t-test was used to evaluate differences between groups. A value of P , 0.05 was considered statistically significant.
Results

Signalling enzymes are involved in
TnTpSer208 expression in failing rat myocardium and cardiac cell models
Cardiac remodelling and dysfunction in these rats characterized at 2 months post-MI showed significant increases in LV end-diastolic pressure, LV end-diastolic and end-systolic diameters, and LV weight. A three-fold decrease in fractional shortening (16 vs. 49%, P , 0.01) and in the contractility and compliance indexes (P , 0.01) indicated systolic and diastolic LV dysfunction (see Supplementary material online, Table  S1 ). As previously shown, TnTpSer208 expression decreased in the LVs of HF rats compared with sham-operated rats ( Figure 1A) . The amino acids surrounding Ser208 are consensus sites for PKC and PP-2A ( Figure 1B) . Neither PP-2A activity (25.6 + 3 vs. 26.2 + 3 nmol/ min/100 mg of proteins) ( Figure 1C , left panel) nor expression of either PP-2A protein ( Figure 1C , middle panel) or its phosphorylated form ( Figure 1C , right panel) changed detectably in the LVs of HF rats, but their LV PKC activity decreased significantly (11 + 2 vs. 20 + 1 ng of active PKC/mg of total proteins, P , 0.05) ( Figure 1D , left panel). We then characterized the expression profile of PKC isoforms. Of the five PKC isoforms (a, bII, d, 1, and z) detected in rat LVs, only PKC1 was modulated significantly; it decreased in ischaemic HF rats (1.5 + 0.2 vs. 2.2 + 0.1, P , 0.01) ( Figure 1D, middle panel) . Modulation of the other isoforms was not significant (see Supplementary material online, Figure S1A ). We measured the amount of PKC1 in both cytosolic (C ) and particulate (P) fractions. The significant decrease of the PKC1 P/(P + C ) ratio found in HF rats compared with their sham-operated controls (39 + 3 vs. 46 + 2, P , 0.05) ( Figure 1D , right panel) suggests a translocation defect in the HF rats.
We then used PKC12/2 mice to demonstrate the direct involvement of PKC1 in TnTSer208 phosphorylation. The PKC1 null phenotype of PKC12/2 mice was verified ( Figure 2A , left panel), and their PKC isoform profile (a, bII, d, and z) studied and found to be the same as the PKC1+/+ mice (see Supplementary material online, Figure S1B ). In this context, PKC12/2 mouse hearts had significantly lower Ser208 TnT phosphorylation levels than the PKC1+/+ mice (0.30 + 0.08 vs. 0.54 + 0.03, P , 0.05) ( Figure 2A , right panel).
PKC1 blockade decreases TnTpSer208 phosphorylation and cardiac contractility
Ex vivo experiments performed in isolated perfused rat hearts (following the design represented in Supplementary material online, Figure S2A) showed that the selective PKC1 inhibitor, 1V1-2, induced marked and significant decreases in LV systolic pressure (68 + 9 vs. 44 + 3 mmHg, P , 0.05) and LV developed pressure (55 + 6 vs. 35 + 2 mmHg, P , 0.05), without any effect on diastolic pressure or coronary flow (data not shown). We verified by SyproRuby staining that the perfusion did not degrade the LV proteins (see Supplementary material online, Figure S2B ). The significant decrease in total PKC activity (23 + 1 vs. 29 + 1, P , 0.01) ( Figure 2B , left panel) and membrane-translocated PKC1 levels (particulate; 0.47 + 0.03 vs. 0.87 + 0.13, P , 0.05) ( Figure 2B , middle panel) in 1V1-2-treated rats, compared with controls, showed effective PKC1 inhibition. 1V1-2 treatment significantly decreased the TnTpSer208/TnT ratio (0.75 + 0.12 vs. 1.51 + 0.08, P , 0.05) ( Figure 2B , right panel) without any change in total TnT expression (data not shown). Despite the significant modulation of the Ser368-phosphorylated connexin 43 (PhosCx43) in the LVs of HF rats compared with sham-operated rats (see Supplementary material online, Figure S3A ), no modulation was observed in 1V1-2-treated rats compared with controls (see Supplementary material online, Figure S3B ).
These results were confirmed in H9c2 cells and NCMs that expressed both TnT and its phosphorylated form (see Supplementary material online, Figure S2C ). H9c2 cell expression of both PKC1 and TnT was also shown by IF ( Figure 2C, left panel) . The treatment of H9c2 cells by increasing concentrations of 1V1-2 for 24 h reduced total PKC activity by as much as 50% (5 mmol/L: 3.9 + 1.1, 10 mmol/L: 4.2 + 0.6 vs. 7.3 + 1.2, P , 0.05) (not shown), and this inhibition was associated ) . B: PKC activity measured in proteins extracted from LVs of isolated perfused rat hearts treated or not with 1V1-2 (100 mL of 200 mmol/L, for 2 ) (n ¼ 6) (left panel). PKC1 subcellular localization measured in cytosolic (C) and particulate (P) fractions. Data are expressed as the PKC1 P/C ratio (middle panel). The TnTpSer208/TnT ratio measured in LVs of controls and 1V1-2-treated rat hearts (n ¼ 7) (right panel). C: Representative IF staining of PKC1 (green) and TnT (red) in untreated H9c2 cells (left panel). H9c2 cells were treated with 1V1-2 (1, 5, and 10 mmol/L, for 24 h, n ¼ 5). PKC1-pSer729 (pPKC1) expression (middle panel) and the TnTpSer208/TnT ratio were measured in untreated and 1V1-2-treated (for 24 h) H9c2 cells (right panel). D: PKC1 silencing was performed in NCMs. Representative IF staining of PKC1 (green) and TnT (red) in primary cultures of NCMs transfected with non-targeting (NT) siRNA control and PKC1 siRNA (n ¼ 5) (left panel). PKC1 expression (middle panel) and the TnTpSer208/TnT ratio were quantified in controls (transfection agent only), non-targeting siRNA (NT), and targeting PKC1 siRNA1-and siRNA2-treated NCMs (n ¼ 5) (right panel). *P , 0.05, **P , 0.01, ***P , 0.001. with a decrease in Ser279-auto-phosphorylated-PKC1 (pPKC1), significant only at 10 mmol/L (0.9 + 0.1 vs. 1.3 + 0.2, P , 0.05) ( Figure 2C , middle panel). Finally, 1V1-2 reduced the TnTpSer208/TnT ratio by almost half (5 mmol/L: 0.7 + 0.1, 10 mmol/L: 0.6 + 0.1 vs. 1.2 + 0.1, P , 0.05) ( Figure 2C, right panel) . As expected, no modulation of the PhosCx43/Cx43 ratio was observed in H9c2 cells treated with 1V1-2 (see Supplementary material online, Figure S3C ), as already published in primary cultures of neonate cardiomyocytes. 24 We also tested the effect of small interfering RNA (siRNA) targeting PKC1 in NCMs ( Figure 2D) . IF showed that a 72 h treatment of NCMs with PKC1 siRNA nearly abolished PKC1 protein expression, with no modulation of TnT expression ( Figure 2D, left panel) . Compared with siRNA NT, siRNA1 and siRNA2 reduced PKC1 by .40 and 30%, respectively ( Figure 2D Figure 2D, right panel) . Interestingly, we also observed that PKC1 silencing significantly decreased the PhosCx43/Cx43 ratio in NCM transfected with PKC1 siRNAs (see Supplementary material online, Figure S3D) .
The results on TnTpSer208 levels of either inhibiting or silencing PKC1 provide strong evidence supporting the hypothesis that PKC1 is specifically involved in TnTpSer208 phosphorylation. We have verified the efficiency of PKC1 silencing in another target, connexin 43, whose role in cardioprotection, after being phosphorylated, recently reviewed. 25 Finally, we used AFM to study the effect of 1V1-2 on the contractility of a single rat NCM ( Figure 3A) , recording for at least 120 min the beating Figure 3B ). 1V1-2 decreased the beating amplitude. This decrease was not due to an unselective loss of contractility, because the cells were still able to increase contraction in response to isoproterenol ( Figure 3C) . Quantification of the beating amplitude of the cardiomyocytes for 10 min showed a significant decrease under 1V1-2 treatment (P ¼ 0.02) and significant restoration after isoproterenol (P , 0.05 vs 1V1-2) ( Figure 3D ). Only isoproterenol, but not 1V1-2, significantly modulated beating frequency of single cardiomyocytes ( Figure 3E ).
Interplay between TnTpSer208 phosphorylation and O-GlcNAcylation in failing rat myocardium
The total level of protein O-GlcNAcylation was significantly higher in the LVs of HF rats compared with sham-operated rats ( Figure 4A) . Interestingly, TnT was found to bear O-GlcNAc residues, and the level of O-GlcNAcylated TnT was higher in the LVs of HF rats ( Figure 4B ). The specificity of the O-GlcNAcylation of TnT was confirmed by treatment of LV proteins with O-GlcNAcase (OGA) to remove all O-GlcNAc moieties (results not shown).
OGT activity increased significantly in the LVs of HF rats (P , 0.05) ( Figure 4C , left panel) while OGA activity decreased significantly (P , 0.05) ( Figure 4C, right panel) . These two enzymes regulate the modification of proteins by O-GlcNAc moieties. Thus, both the increase of OGT and the decrease of OGA activity in HF rat LVs may contribute to the observed increase of total protein O-GlcNAcation ( Figure 4A) and O-GlcNAcylated TnT ( Figure 4B) . OGT, the enzyme that carries O-GlcNAc moieties to the proteins, was also detected in TnT-positive NCMs by immnuofluorescence ( Figure 4D) .
To determine the existence of interplay between the phosphorylation and O-GlcNAcylation of TnT, we quantified the levels of O-GlcNAcylated TnT in the LVs of control and 1V1-2 treated rat hearts and found that the level of the O-GlcNAcylated form increased significantly after PKC1 inhibition ( Figure 4E ) and was inversely related to the levels of phosphorylated TnT ( Figure 2B, right panel) .
To confirm these data, we tested several modulators of O-GlcNAcylation. First, in isolated perfused hearts, we assessed the functional cardiac modification induced by Thiamet G, a specific OGA inhibitor, injected 2 h before the perfusion (see Supplementary material online, Figure S2A ). Thiamet G decreased the coronary flow significantly (29 + 1 vs. 21 + 6 mL/min, P , 0.05) without affecting LV pressures (data not shown), as well as OGA activity ( Figure 5A , left panel) and levels of O-GlcNAcylated LV proteins (1.0 + 0.1 vs. 1.4 + 0.1, P , 0.05; Figure 5A , middle and right panel). We then studied the impact of OGA inhibition on TnT phosphorylation and observed that Thiamet G significantly decreased the TnTpSer208/TnT ratio (0.83 + 0.11 vs. Figure 5B ). We also tested the effect of siRNA that targeted OGT in NCMs ( Figure 5C ) and found that a 72 h treatment of the NCMs with OGT siRNA abolished OGT protein expression ( Figure 5C , upper panels) and decreased the levels of protein O-GlcNAcylation ( Figure 5C , lower panels). Both OGT siRNA1 and siRNA 2 significantly increased the TnTpSer208/TnT ratio (1.64 + 0.29 for siRNA1 and 1.89 + 0.28 for siRNA2, vs. 1.25 + 0.25 for NT, P , 0.05) ( Figure 5D ). These data showed the reciprocal relation between TnT phosphorylation and O-GlcNAcylation.
To determine whether TnT can be simultaneously phosphorylated and O-GlcNAcylated in rat LVs, we fractionated the LV proteins by O-GlcNAc immunoprecipitation into two protein pools: one O-GlcNAcylated and the other not and quantified the TnTpSer208 and TnT in each pool ( Figure 6A, left panel) . We verified that the overall pool of LV proteins expressed O-GlcNAcylated proteins, TnTpSer208, and TnT ( Figure 6A, middle panel) . Interestingly, TnTpSer208 was detected only in the non-O-GlcNAcylated subpopulation, in contrast to TnT, which was detected in both subpopulations ( Figure 6A, right panel) . This suggests that TnT cannot be simultaneously phosphorylated on Ser208 and O-GlcNAcylated on Ser190 in the heart.
To identify the O-GlcNAc sites in TnT, we previously used 2D polypeptide spots 11 isolated from the LVs of HF rats to map three sites of O-GlcNAcylation. Three peptides encompassing these potential sites were incubated with ncOGT protein to detect the presence of O-GlcNAc species. An additional signal matching the incorporation of an O-GlcNAc moiety ( Figure 6B ) was found only in the peptide encompassing the region from residues 184 to 196 in TnT (peptide TnT2, see Supplementary material online, Table S2 ). This peptide contained only one serine residue, at position 190. This finding thus unambiguously identified the O-GlcNAcylation site; moreover, it was confirmed by NMR spectroscopy. Indeed, in the O-GlcNAc-enriched TnT2 peptide, the detection of characteristic scalar correlations between the acetamide proton of the O-GlcNAc moiety and the protons of the pyranoside ring (from the anomeric H1 to H4) indicated the presence of an O-b-GlcNAcylated residue ( Figure 6C ). We also used Ha and Hb as useful identifier signals since modifications of their chemical shifts are accurately associated with an O-GlcNAc addition to a serine or threonine residue. 26 Here, we observed the largest chemical shift perturbations for Ha and Hb resonances of S190 ( Figure 6D ). These combined experiments enabled us to identify for the first time the O-GlcNAcylation of cardiac TnT on Ser190. 
Discussion
PTMs of sarcomeric proteins play an important role in HF-induced cardiac dysfunction. 11, 27 While studying alterations of the phosphoproteome in HF, we previously reported a reduced myocardial level of TnTpSer208 in post-MI failing rat hearts 11, 12 and reduced circulating levels of TnTpSer208 in post-MI patients, correlated with the development of adverse LV remodelling. This Ser208 is located in a TNT region with highly conserved homology across species. 28 These findings prompted us to examine (i) the kinase/phosphatase regulation involved in the decreased TnTSer208 phosphorylation after MI; (ii) the possibility of TnT O-GlcNAcylation and the identity of the main enzymes regulating O-GlcNAc PTM; and (iii) the interplay between phosphorylation and O-GlcNAcylation in cardiac TnT.
Recent studies have shown that one contributor to post-MI cardiac dysfunction during heart failure is the changed balance between the kinases and phosphatases that coordinate phosphorylation of the proteins involved in cardiomyocyte contractility. 29 We therefore analysed the expression of PP-2A 30 and of the different PKC isoforms previously reported to be involved in this phosphorylation. 31 -34 As reported, LV PP-2A activity was not modified in HF rats, 30 nor were levels of the catalytic subunit of PP-2A at Tyr307. 35 These findings suggest that the decreased level of TnTpSer208 level is not attributable to direct phosphatase regulation. Previous work reported four main sites for PKC-dependent phosphorylation on bovine cardiac TnT: Thr197, Ser201 (corresponding to Ser208 in this paper), Thr206, and Thr287. 31 We showed that LV PKC1 expression and activity are significantly lower in HF than in control rats. These data are in accordance with the physical association of PKC1 and TnT identified by coimmunoprecipitation with cardiac proteins 36 and with in vitro phosphorylation experiments showing that the synthetic peptide corresponding to the 191-299 TnT sequence was the best substrate for PKC1, despite its lower efficiency than the native TnT. 31 Reports about the expression of different PKC isoforms and the modulation of their activity are nonetheless divergent. The expression of these isoforms may depend on the duration (acute vs. chronic/end stage) or cause of HF (ischaemic or non-ischaemic origin), or the species used. 37 We also observed that PKCbII isoform was expressed more than PKC1 in both mouse and rat LV but that this difference was more marked in mouse than in rat LV. Selective inhibition of PKC1 either by gene deletion (PKC12/2 transgenic mice), pharmacological or silencing in cultured cardiomyocytes induced a decrease of TnTpSer208/TnT ratio demonstrating that Ser208 of TnT may be a specific target of PKC1. In addition, a constitutive PKC1 overexpression in mouse myocardium did not change the expression of other PKC isoforms, similar to our results in PKC12/2 mice and increased phosphorylation of TnI and TnT. 38 Pharmacological inhibition of PKC1 reduced cardiac contractility in isolated perfused rat hearts, consistent with defective active PKC1 translocation 39 that may also regulate myofilament activity. 40 Interestingly, using AFM, which is reported to quantify the beat force of single cells and clusters of cardiomyocytes, 41 we showed that PKC1 inhibition decreased beating amplitude without modifying the beating frequency in single cardiomyocytes. In a previous work, the functionality of the four PKC-dependent phosphorylation sites identified in TnT was tested on myofilament properties and energetics, showing that Thr206 was a functionally critical cTnT-PKC phosphorylation residue involving PKCa. 42 In fact, their data also showed that phosphorylation of TnT by PKCa was not sufficient for complete tension and actomyosin Mg-ATPase activity observed in fibre bundles. Importantly, they also showed a decreased tension and actomyosin Mg-ATPase activity with TnT containing the four mutated PKC sites, including Ser201, compared with the activity of TnT with only the three Thr mutated by Ala. 42 In fact, recently no modulation of cTnT specifically phosphorylated at Thr206 or Thr279 was found in the LV of chronic HF rats, in contrast to the RV, 43 corroborating our data that only Ser-phosphorylated TnT was modulated in the LV of ischaemic HF rats.
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Protein O-GlcNAcylation increased in HF rats, as others have shown, 44, 45 due both to increased OGT and decreased OGA activity.
For the first time, we observed an O-GlcNAcylated form of cardiac TnT in the heart; its level increased during HF and was inversely correlated with the phosphorylation of TnT on Ser208. Site mapping of O-GlcNAc in TnT showed for the first time that Ser 190 is the O-GlcNAcylated residue. Interestingly, PKC1 inhibition increased the level of O-GlcNAcylated forms of cardiac TnT, thereby suggesting possible crosstalk between its phosphorylation and O-GlcNAcylation. Interestingly, modulation of O-GlcNAcylation either by OGA inhibition or OGT silencing reduced or increased TnTpSer208 phosphorylation, respectively. O-GlcNAc modifications can modulate protein stability and functions and are implicated in cardiovascular diseases. 46 X-box binding protein 1, a transcription factor involved in unfolded protein response, has recently been shown to be a direct inducer of O-GlcNAc modifications that protect cardiomyocytes. 47 We might speculate that the decreased TnTpS208 phosphorylation observed during HF is a signal for cardiomyocyte protection that enables the level of the O-GlcNAcylated TnT form to rise as an adaptive mechanism.
Thus, despite the limitation of our study about the mechanistic link to function of these modifications of TnT, our data show that (i) HF induces a decrease in TnTpSer208 phosphorylation, most likely due to decreased PKC1 expression and activity, and an increase in TnTSer190 O-GlcNAcylation, associated with decreased OGA activity and increased OGT activity; (ii) increasing O-GlcNAcylation decreases TnTpSer208 levels, while reducing O-GlcNAcylation increases them; (3) cardiac TnT phosphorylated on Ser208 was not detected in the non-O-GlcNAcylated subpopulation. These data demonstrate the existence of a reciprocal relation between phosphorylation and O-GlcNAcylation of TnT during the development of HF.
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